Estrella Immunopharma, Inc.
ESLA · NASDAQ
12/31/2024 | 6/30/2024 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6,409 | $4,109 | $0 | $1,389 |
| G&A Expenses | $1,420 | $3,201 | $0 | $296 |
| SG&A Expenses | $2,437 | $3,201 | $1,368 | $296 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $201 | $0 |
| Operating Expenses | $8,846 | $7,310 | $1,570 | $1,685 |
| Operating Income | -$8,846 | -$7,310 | -$1,570 | -$1,685 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $654 | $1,438 |
| Pre-Tax Income | -$8,846 | -$7,310 | -$915 | -$1,685 |
| Tax Expense | $2 | $2 | $81 | -$235 |
| Net Income | -$8,848 | -$7,312 | -$996 | -$1,685 |
| % Margin | – | – | – | – |
| EPS | -0.25 | -0.21 | -0.17 | -0.29 |
| % Growth | -19% | -23.5% | 41.4% | – |
| EPS Diluted | -0.25 | -0.21 | -0.17 | -0.29 |
| Weighted Avg Shares Out | 36,681 | 35,201 | 5,763 | 5,850 |
| Weighted Avg Shares Out Dil | 36,681 | 35,201 | 5,763 | 5,850 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $654 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$40 | $0 | $228 | $237 |
| EBITDA | -$8,846 | -$7,310 | -$687 | -$11 |
| % Margin | – | – | – | – |